Tirzepatide

## Mechanism of Action

Tirzepatide is a synthetic peptide that activates both GIP and GLP-1 receptors, making it the first dual incretin receptor agonist approved for clinical use. GIP and GLP-1 are incretin hormones released by the intestine in response to food intake. By stimulating these receptors, tirzepatide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release when blood glucose is elevated, slows gastric emptying, and reduces appetite through central nervous system pathways. The dual-receptor mechanism distinguishes tirzepatide from single GLP-1 receptor agonists like semaglutide and liraglutide.

## Clinical Use and Evidence

The SURPASS clinical trial program evaluated tirzepatide in adults with type 2 diabetes. In the SURPASS-2 trial published in *The New England Journal of Medicine* in 2021 (PMID: 34170647), tirzepatide 5mg, 10mg, and 15mg weekly demonstrated superior HbA1c reductions compared to semaglutide 1mg weekly over 40 weeks, with mean HbA1c reductions of 2.01%, 2.24%, and 2.30% respectively versus 1.86% for semaglutide.

For weight management, the SURMOUNT-1 trial published in *The New England Journal of Medicine* in 2022 (PMID: 35658024) enrolled 2,539 adults with obesity or overweight and at least one weight-related comorbidity (excluding diabetes). Over 72 weeks, participants receiving tirzepatide 5mg, 10mg, or 15mg weekly achieved mean weight reductions of 15.0%, 19.5%, and 20.9% from baseline, compared to 3.1% in the placebo group. These are among the largest weight reductions observed in pharmacotherapy trials to date.

## Regulatory Status: Branded vs. Compounded

The FDA approved tirzepatide under two brand names for distinct indications:

- **Mounjaro** (approved May 2022): indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. - **Zepbound** (approved November 2023): indicated for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.

Both branded products are manufactured by Eli Lilly and contain tirzepatide in pre-filled, single-dose pens with specific excipients and preservatives.

**Compounded tirzepatide** preparations are made by state-licensed compounding pharmacies when a valid prescription is provided and certain conditions are met (such as drug shortages or patient-specific needs that the commercial product cannot address). Compounded tirzepatide is not an FDA-approved drug product. Compounded formulations may differ in concentration, excipients, sterility assurance, and dosing accuracy. The FDA does not review compounded medications for safety or efficacy prior to dispensing. Patients considering compounded tirzepatide should discuss the distinction with a licensed healthcare provider.

## Who May Be a Candidate

Tirzepatide (branded formulations) may be appropriate for adults with:

- Type 2 diabetes who have not achieved glycemic targets with metformin or other oral agents. - Obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea.

Tirzepatide is administered as a once-weekly subcutaneous injection, typically starting at 2.5mg weekly and titrating upward every 4 weeks based on tolerability and clinical response. Maximum doses are 15mg weekly for diabetes (Mounjaro) and 15mg weekly for weight management (Zepbound).

**Contraindications and precautions** include:

- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tirzepatide carries a boxed warning for thyroid C-cell tumors observed in rodent studies. - History of severe gastrointestinal disease, including gastroparesis or inflammatory bowel disease. - History of pancreatitis. - Pregnancy or breastfeeding (tirzepatide is not recommended). - Concurrent use of other GLP-1 receptor agonists or rapid-acting insulin without dose adjustment.

Tirzepatide slows gastric emptying, which may affect the absorption of oral medications. Patients on warfarin or other medications with narrow therapeutic indices should be monitored closely.

## Common and Serious Side Effects

The most frequently reported side effects in clinical trials were gastrointestinal: nausea (12-29% depending on dose), diarrhea (12-16%), vomiting (5-9%), constipation (6-7%), and abdominal pain. These effects were generally mild to moderate and decreased over time. Dose titration every 4 weeks, rather than more rapid escalation, reduces GI intolerance.

**Serious adverse events** reported in clinical trials and post-marketing include:

- **Hypoglycemia**: more common when tirzepatide is used with insulin or sulfonylureas. Dose reduction of concomitant insulin or sulfonylurea may be required. - **Acute pancreatitis**: rare but serious. Patients should be advised to report severe, persistent abdominal pain. - **Gallbladder disease**: cholelithiasis and cholecystitis were reported more frequently in tirzepatide-treated patients than placebo. Weight loss itself is a known risk factor for gallstone formation. - **Acute kidney injury**: reported in patients experiencing severe gastrointestinal side effects leading to dehydration. Monitoring renal function in at-risk patients is recommended. - **Diabetic retinopathy complications**: worsening of diabetic retinopathy was observed in some diabetes trials, particularly in patients with rapid glucose reduction. Patients with pre-existing retinopathy should be monitored. - **Thyroid C-cell tumors**: boxed warning based on rodent data. Human relevance is unknown, but tirzepatide should not be used in patients with a personal or family history of MTC or MEN 2.

Suicidal ideation and behavior have been reported with GLP-1 receptor agonists; the FDA is investigating. Patients and providers should monitor for mood changes.

## When to Talk to a Provider

Tirzepatide requires a prescription from a licensed healthcare provider. Telehealth platforms like ZYNDIO connect adults with licensed clinicians who can evaluate eligibility, order baseline labs (such as HbA1c, lipid panel, renal function), prescribe tirzepatide if appropriate, and provide ongoing monitoring. A telehealth provider will assess medical history, current medications, contraindications, and weight or diabetes management goals.

Patients prescribed tirzepatide should have follow-up visits every 4-12 weeks initially to assess tolerability, titrate dose, monitor for side effects, and review labs. Long-term use requires ongoing provider supervision. If gastrointestinal symptoms are severe or persistent, if hypoglycemia occurs, or if signs of pancreatitis or gallbladder disease develop, patients should contact their provider immediately.

## Frequently Asked Questions

**Is compounded tirzepatide the same as Mounjaro or Zepbound?**

No. Compounded tirzepatide is not an FDA-approved drug product. It is prepared by state-licensed compounding pharmacies and may differ in formulation, concentration, excipients, and quality assurance processes. Branded tirzepatide (Mounjaro, Zepbound) is manufactured under FDA oversight with consistent dosing and sterility. Compounded versions are typically pursued when the branded product is unavailable due to shortage, when insurance does not cover the branded product, or when a patient has a documented allergy to an excipient in the commercial formulation. Patients should discuss the risks and benefits of compounded versus branded tirzepatide with a licensed provider.

**How long does it take to see results with tirzepatide?**

Weight loss typically becomes noticeable within 4-8 weeks of starting tirzepatide, with continued weight reduction over 6-12 months as the dose is titrated. In the SURMOUNT-1 trial, participants reached maximum weight loss at approximately 72 weeks. HbA1c reductions in diabetes trials were observed within 12 weeks. Individual results vary based on baseline weight, adherence to diet and exercise, dose, and metabolic factors.

**Can I stop tirzepatide once I reach my goal weight?**

Tirzepatide is intended for chronic use. In clinical trials, discontinuation led to weight regain in most participants. The SURMOUNT-4 trial (PMID: 37385275) demonstrated that participants who discontinued tirzepatide after 36 weeks regained approximately 14% of body weight over the subsequent 52 weeks, while those who continued tirzepatide maintained weight loss. Patients should discuss long-term treatment plans with their provider. Some may transition to lifestyle modification alone; others may require ongoing therapy.

**Does insurance cover tirzepatide for weight loss?**

Coverage varies by insurance plan. Mounjaro (for diabetes) is more widely covered than Zepbound (for weight management). Many commercial and Medicare Part D plans exclude or restrict coverage for weight-loss medications. Patients may use manufacturer savings programs, such as the Mounjaro or Zepbound Savings Card (if eligible), or consider compounded tirzepatide through telehealth pharmacies, which may offer lower out-of-pocket costs. ZYNDIO connects patients with licensed providers and partners with state-licensed compounding pharmacies to provide access when branded products are cost-prohibitive or unavailable.

**What should I do if I miss a dose?**

If a dose is missed and it has been fewer than 4 days since the scheduled dose, administer the injection as soon as possible. If more than 4 days have passed, skip the missed dose and resume the regular weekly schedule. Do not administer two doses within 3 days of each other. Consult the prescribing information or contact your provider if unsure.

**Medical Disclaimer**

The information in this article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. ZYNDIO connects adults with licensed providers via telehealth; the providers — not ZYNDIO — make all clinical decisions. Compounded medications dispensed through ZYNDIO partners are not FDA-approved drug products. They are prepared by state-licensed compounding pharmacies pursuant to a valid prescription. Individual results vary. Side effects, drug interactions, and contraindications exist for every therapy discussed here.

Last reviewed: 2026-04-25 by ZYNDIO Clinical Editorial Team (PharmD-led)